Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 13/20 | 0.52 |
| ▸ | FKBP4 | Q02790 | 2/20 | 0.52 |
| ▸ | FKBP5 | Q13451 | 2/20 | 0.52 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.50 |
| ▸ | PTAFR | P25105 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16586222 | 1.00 | FKBP1A (0.52) | FKBP1AFKBP4FKBP5ABCC1PTAFR | |
| SCHEMBL7220110 | 0.87 | FKBP1A (0.53) | FKBP1A | |
| SCHEMBL27475679 | 0.81 | FKBP1A (0.57) | FKBP1A | |
| SCHEMBL13938148 | 0.81 | FKBP1A (0.52) | FKBP1AFKBP4FKBP5ABCC1TBXAS1 | |
| SCHEMBL6926542 | 0.80 | FKBP1A (0.54) | FKBP1AFKBP4FKBP5 | |
| SCHEMBL7757112 | 0.80 | FKBP1A (0.54) | FKBP1AFKBP4FKBP5 | |
| SCHEMBL3674851 | 0.79 | FKBP1A (0.47) | FKBP1A | |
| SCHEMBL3676924 | 0.74 | FKBP1A (0.65) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL3676926 | 0.74 | FKBP1A (0.65) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL5017050 | 0.73 | FKBP1A (0.65) | FKBP1AFKBP4FKBP5ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030556-B1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-10246413-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-04-02 | — | — | US | disclosed |
| US-10246413-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-04-02 | — | — | US | disclosed |
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-9845292-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-19 | — | — | US | disclosed |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | HAUSCH, FELIX (DE) | 2016-10-06 | — | — | US | disclosed |
| EP-1138673-B1 | Novel carbamates and ureas as modifiers of multi-drug resistance | VERTEX PHARMA (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1666053-A1 | Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors | Vertex Pharmceuticals Incorporated (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-0754176-B1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | VERTEX PHARMA (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-1138673-A2 | Novel carbamates and ureas as modifiers of multi-drug resistance | Vertex Pharmaceuticals Incorporated (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-0941113-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS | Vertex Pharmaceuticals Incorporated (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5780484-A | Methods for stimulating neurite growth with piperidine compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998020893-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-05-22 | — | — | WO | disclosed |
| US-5744485-A | INCREASE SENSITIVITY OF CELLS; CANCER | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0754176-A1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | Vertex Pharmaceuticals Incorporated (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995026337-A1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072667-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP5, FKBP1A, FKBP3 | FKBP1A 2/4885FKBP4 5/4885FKBP5 1/4885 |
| US-10246413-B2 | Selective FKBP51 ligands for treatment of psychiatric disorders | FKBP5, FKBP1A, FKBP3 | FKBP1A 2/4885FKBP4 5/4885FKBP5 1/4885 |
| US-20160289184-A1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP5, FKBP1A, FKBP1B | FKBP1A 2/4885FKBP4 6/4885FKBP5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.